Has Anyone Not Lost Weight on Mounjaro — and What Should You Do About It?

Step 1: Understand what the trial data actually shows about the range of responses

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and followed them for 72 weeks. The average weight reduction at the highest dose (15mg) was around 20–21%. That figure gets quoted widely, but averages conceal a broad distribution. Some participants lost more than 25% of their body weight. Others lost well under 10%, and a small number lost very little. Every large randomised trial of this kind contains non-responders; this one is no different.

There is also an important timing point. Tirzepatide begins at 2.5mg as a tolerability dose, not a therapeutic one. The first pen's job is to settle your system. Most prescribers expect to see meaningful progress only once a patient has been on a stable, higher dose for several weeks. Judging the medicine's effectiveness at 2.5mg or 5mg, in the first month or two, is likely to give a misleading picture.

So if you are asking whether anyone has not lost weight on Mounjaro: yes. But asking why, and at what dose and timepoint, is the more useful question. Our Mounjaro overview sets out the full clinical picture if you want the broader background.

Step 2: Work through the most common reasons progress stalls

Non-response or slow response usually falls into one of a handful of identifiable categories. Dose is the most obvious: if you are still on a lower rung of the titration schedule, it is too early to conclude the medicine is not working. Duration matters too, some people start losing weight a few weeks after others on identical doses.

Diet is another factor the evidence is clear about. Tirzepatide reduces appetite and slows gastric emptying, but it does not override a significant caloric surplus. If your eating patterns have not shifted alongside the medicine, the effect may be blunted. Protein intake specifically matters: under-eating protein can mean the weight lost comes partly from muscle rather than fat tissue, which affects both how the scales move and how you feel.

Certain medicines can interfere with progress. Insulin and some antidepressants are known to affect weight; so can steroids. If you started a new medication around the same time as Mounjaro, that is worth discussing with your prescriber. Thyroid function is another common culprit: unmanaged hypothyroidism makes weight loss significantly harder regardless of treatment.

Practical habits count, too. Keeping your pen in the fridge door and injecting on the same day each week removes the inconsistency of forgotten or delayed doses, a source of reduced effect that is easily overlooked. Using Mounjaro swabs to clean the injection site each time is a simple step that supports consistent and hygienic administration. The full breakdown of reasons covers each of these in more detail.

Step 3: Know when to raise it with your prescriber, and what they can actually do

The right moment to flag slow progress is at your clinical review before your next supply. This is not a formality. A GPhC-registered Independent Prescriber looking at your case can consider whether your current dose is appropriate, whether an interfering factor should be addressed first, or whether a different approach makes more sense. That might mean continuing at the current dose for longer, titrating to the next level, or reviewing what else is going on.

What it should not mean is self-managing a dose increase. Changing your injecting schedule, skipping weeks, or doubling up carries real risks and is contrary to the guidance in the Patient Information Leaflet. The NHS tirzepatide page is a clear reference for what the medicine is licensed to do and how to use it safely.

Some people do consider switching to a different treatment if progress remains poor despite an adequate trial. That is a clinical conversation. Our treatment overview explains the licensed options available in the UK. For context on costs if you are reviewing your options, the Mounjaro price comparison page sets out what UK private treatment typically involves and what any legitimate price should include.

Step 4: Check whether Mounjaro was the right fit to begin with

Tirzepatide is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition. Lower thresholds can apply for some ethnic backgrounds under UK guidance. But eligibility on paper does not guarantee a strong response for any individual. Biology, existing conditions, other medicines, and lifestyle all interact with the treatment. That is precisely why the assessment exists.

A prescriber who understands your full medical picture is better placed than anyone to judge whether the medicine has had a fair trial, whether you meet the criteria for continuing, and what the next step should be. Not everyone is clinically suitable, and not everyone who is suitable will respond the same way. Our clinical team reviews every case individually, there is no algorithm making that call. If you have concerns about your progress, the most useful first step is a proper clinical review.